Jiangsu Hengrui Pharmaceuticals Co.,Ltd is a prominent player in the Healthcare sector, specifically operating within the Specialty and Generic Drug Manufacturers industry. The company currently boasts a substantial market capitalization of 335.11 Billion. Despite its significant market presence, recent short-term trading data reveals a challenging landscape, with the stock experiencing a notable 7-day decline of 9.61% and closing at CNY 50.49.
Based on our proprietary technical scoring system, Jiangsu Hengrui Pharmaceuticals Co.,Ltd has been assigned a Strong Sell rating, reflecting a total score of -4 out of an available range of -6 to +6. This bearish outlook is primarily driven by multiple negative technical indicators. The most significant downward pressure comes from the stock's prevailing trend: the current price (CNY 50.49) is trading well below its 200-day Simple Moving Average (CNY 60.81), yielding a core trend score of -2. Furthermore, the MACD histogram sits in negative territory (-0.38), indicating a bearish crossover. The On-Balance Volume (OBV) is also trailing below its 5-day moving average, signaling ongoing distribution and selling pressure from investors. The ADX remains low at 10.15, highlighting a lack of strong directional momentum, while the RSI sits at a neutral 34.01, just above the oversold threshold, failing to offer any immediate signs of a reversal.
Fundamentally, this weak technical setup largely aligns with concerning recent performance metrics. The company carries a relatively high Price-to-Earnings (P/E) ratio of 41.05, suggesting a premium valuation that is difficult to justify given recent earnings misses. Most notably, the latest reported EPS was 0.22, which came with a stark negative earnings surprise of -248.0%. Although the recorded dividend yield is exceptionally high at 39.0%, such elevated yields are often a byproduct of severe stock price depreciation rather than sustainable cash returns. With the next earnings date currently unannounced (N/A), the convergence of severe fundamental earnings misses and technical deterioration firmly supports a cautious, bearish stance.